Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
作者信息
Slaven James E, Decker Brian S, Kashuba Angela D M, Atta Mohamed G, Wyatt Christina M, Gupta Samir K
机构信息
Department of Biostatistics, Indiana University School of Medicine.
Division of Nephrology, Indiana University School of Medicine.
出版信息
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e8-e10. doi: 10.1097/QAI.0000000000001106.
Abstract
摘要
相似文献
1
Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.接受富马酸替诺福韦二吡呋酯和恩曲他滨治疗的需要血液透析的HIV感染患者的血浆和细胞内浓度
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e8-e10. doi: 10.1097/QAI.0000000000001106.
2
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.药物停用后血浆中替诺福韦、恩曲他滨和利匹韦林以及细胞内二磷酸替诺福韦和三磷酸恩曲他滨的药代动力学。
Antimicrob Agents Chemother. 2015 Oct;59(10):6080-6. doi: 10.1128/AAC.01441-15. Epub 2015 Jul 20.
3
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.恩曲他滨/利匹韦林/富马酸替诺福韦二吡呋酯片治疗成人 HIV-1 感染。
J Infect Public Health. 2015 Sep-Oct;8(5):409-17. doi: 10.1016/j.jiph.2015.04.020. Epub 2015 May 19.
4
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.HIV DNA耐药基因型检测在适合换用rilpivirine/恩曲他滨/替诺福韦酯富马酸盐组合的患者中的应用价值。
J Antimicrob Chemother. 2016 Aug;71(8):2248-51. doi: 10.1093/jac/dkw146. Epub 2016 May 26.
5
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.转为以埃替格韦/考比司他/恩曲他滨/替诺福韦酯富马酸盐作为维持治疗：临床队列研究的第48周结果
J Antimicrob Chemother. 2017 Jun 1;72(6):1745-1751. doi: 10.1093/jac/dkx018.
6
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.从利匹韦林/替诺福韦二吡呋酯富马酸/恩曲他滨转换为利匹韦林/替诺福韦艾拉酚胺/恩曲他滨后血脂谱的变化：基线高胆固醇血症患者与无基线高胆固醇血症患者的不同影响。
PLoS One. 2019 Oct 11;14(10):e0223181. doi: 10.1371/journal.pone.0223181. eCollection 2019.
7
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.在一项转换为替诺福韦/恩曲他滨/利匹韦林的队列研究中PCR信号的应用及治疗药物监测：W96随访
PLoS One. 2015 Jul 30;10(7):e0134430. doi: 10.1371/journal.pone.0134430. eCollection 2015.
8
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.在人类免疫缺陷病毒1感染且RNA得到抑制的患者中转换为rilpivirine/恩曲他滨/替诺福韦单片治疗方案：96周时的有效性、安全性和成本
Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12968. Epub 2017 Jul 19.
9
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.瑞士HIV队列研究中rilpivirine的使用：一项前瞻性队列研究。
BMC Infect Dis. 2017 Jul 6;17(1):476. doi: 10.1186/s12879-017-2579-2.
10
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.既往核苷类反转录酶抑制剂（NRTI）和非核苷类反转录酶抑制剂（NNRTI）耐药性对转换为替诺福韦/恩曲他滨/利匹韦林单片剂方案的HIV-1感染患者病毒学抑制维持情况的影响。
J Antimicrob Chemother. 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512.
引用本文的文献
1
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection.CD8+ 细胞和小病毒库有助于在感染后两周开始接受 ART 的 M3+毛里求斯食蟹猴模型中控制 SIV 复制。
PLoS Pathog. 2023 Sep 25;19(9):e1011676. doi: 10.1371/journal.ppat.1011676. eCollection 2023 Sep.
2
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaques.CD8 +细胞和小型病毒库有助于毛里求斯食蟹猕猴在抗逆转录病毒治疗后对猴免疫缺陷病毒的控制。
bioRxiv. 2023 Mar 2:2023.03.01.530655. doi: 10.1101/2023.03.01.530655.
3
Pharmacotherapeutic options for kidney disease in HIV positive patients.HIV 阳性患者肾病的药物治疗选择。
Expert Opin Pharmacother. 2021 Jan;22(1):69-82. doi: 10.1080/14656566.2020.1817383. Epub 2020 Sep 21.
4
Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.肾功能损害患者的新型抗逆转录病毒药物：临床和药代动力学考量
Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):559-572. doi: 10.1007/s13318-016-0394-6.
本文引用的文献
1
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.一种转化药理学方法，用于预测使用富马酸替诺福韦二吡呋酯联合或不联合恩曲他滨对男性和女性进行暴露前预防艾滋病毒的结果。
J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.
2
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯、艾维雷韦、考比司他、恩曲他滨复方制剂，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗：两项随机、双盲、III 期、非劣效性试验。
Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
3
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.接受暴露前预防（PrEP）的男男性行为者的恩曲他滨替诺福韦浓度与预防效果。
Sci Transl Med. 2012 Sep 12;4(151):151ra125. doi: 10.1126/scitranslmed.3004006.
4
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.TMC114/利托那韦与替诺福韦酯在健康志愿者中的药代动力学相互作用。
Br J Clin Pharmacol. 2007 Nov;64(5):655-61. doi: 10.1111/j.1365-2125.2007.02957.x. Epub 2007 Jul 4.
5
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.富马酸替诺福韦二吡呋酯在肝损伤或肾损伤患者中的药代动力学及给药建议
Clin Pharmacokinet. 2006;45(11):1115-24. doi: 10.2165/00003088-200645110-00005.
6
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.接受三联核苷治疗方案患者中替诺福韦二磷酸酯、卡波韦三磷酸酯和拉米夫定三磷酸酯的细胞内药代动力学。
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11. doi: 10.1097/01.qai.0000167155.44980.e8.
7
Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.高效抗逆转录病毒疗法与HIV阳性终末期肾病的流行
J Am Soc Nephrol. 2005 Aug;16(8):2412-20. doi: 10.1681/ASN.2005040340. Epub 2005 Jun 29.
8
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.恩曲他滨与拉米夫定短期单药治疗人类免疫缺陷病毒感染患者的前瞻性随机试验。
J Infect Dis. 2003 Dec 1;188(11):1652-8. doi: 10.1086/379667. Epub 2003 Oct 31.
9
Pharmacokinetics of tenofovir in haemodialysis.
Nephrol Dial Transplant. 2003 Sep;18(9):1931-3. doi: 10.1093/ndt/gfg327.
10
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).抗逆转录病毒药物快速剂量选择的原型试验设计：以恩曲他滨（替诺福韦）为例
J Antimicrob Chemother. 2001 Oct;48(4):507-13. doi: 10.1093/jac/48.4.507.
Zotero 插件